Related references
Note: Only part of the references are listed.Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)-a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma
Susanne Flach et al.
BRITISH JOURNAL OF CANCER (2022)
Phase I Trial of Cetuximab, Radiotherapy, and Ipilimumab in Locally Advanced Head and Neck Cancer
Robert L. Ferris et al.
CLINICAL CANCER RESEARCH (2022)
The future of circulating tumor DNA as a biomarker in HPV related oropharyngeal squamous cell carcinoma
Catherine T. Haring et al.
ORAL ONCOLOGY (2022)
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial
Assuntina G. Sacco et al.
LANCET ONCOLOGY (2021)
Integrative sequencing discovers an ATF1-motif enriched molecular signature that differentiates hyalinizing clear cell carcinoma from mucoepidemoid carcinoma
M. E. Heft Neal et al.
ORAL ONCOLOGY (2021)
Paired phase II trials evaluating cetuximab and radiotherapy for low risk HPV associated oropharyngeal cancer and locoregionally advanced squamous cell carcinoma of the head and neck in patients not eligible for cisplatin
Paul L. Swiecicki et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2020)
Prognostic Significance of Oxidation Pathway Mutations in Recurrent Laryngeal Squamous Cell Carcinoma
Molly E. Heft Neal et al.
CANCERS (2020)
Treatment sequence of cetuximab and immune checkpoint inhibitor in head and neck squamous cell carcinoma differentially affects outcomes
Jong Chul Park et al.
ORAL ONCOLOGY (2020)
Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Miren Taberna et al.
FRONTIERS IN ONCOLOGY (2019)
Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use
Robert L. Ferris et al.
CLINICAL CANCER RESEARCH (2019)
Heterogeneity of the Head and Neck Squamous Cell Carcinoma Immune Landscape and Its Impact on Immunotherapy
Madison Canning et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2019)
Analysis of tumor-infiltrating CD103 resident memory T-cell content in recurrent laryngeal squamous cell carcinoma
Jacqueline E. Mann et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Ezra E. W. Cohen et al.
LANCET (2019)
Evaluation of the eighth TNM classification on p16-positive oropharyngeal squamous cell carcinomas in the Netherlands and the importance of additional HPV DNA testing
I. H. Nauta et al.
ANNALS OF ONCOLOGY (2018)
Proportion of CD4 and CD8 tumor infiltrating lymphocytes predicts survival in persistent/recurrent laryngeal squamous cell carcinoma
Rebecca Hoesli et al.
ORAL ONCOLOGY (2018)
Human Papillomavirus Testing in Head and Neck Carcinomas: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists Guideline
Carole Fakhry et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Correlation of Crtc1/3-Maml2 fusion status, grade and survival in mucoepidermoid carcinoma
Andrew C. Birkeland et al.
ORAL ONCOLOGY (2017)
Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma
Axel Lechner et al.
ONCOTARGET (2017)
Increased PD-1+ and TIM-3+ TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients
Hyun-Bae Jie et al.
CANCER IMMUNOLOGY RESEARCH (2017)
The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer A Secondary Analysis of a Randomized Clinical Trial
Joanne B. Weidhaas et al.
JAMA ONCOLOGY (2017)
Fibroblast growth factor family aberrations as a putative driver of head and neck squamous cell carcinoma in an epidemiologically low-risk patient as defined by targeted sequencing
Brittny N. Tillman et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2016)
Identification of Targetable ERBB2 Aberrations in Head and Neck Squamous Cell Carcinoma
Andrew C. Birkeland et al.
JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY (2016)
CTLA-4+ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis
Hyun-Bae Jie et al.
CANCER RESEARCH (2015)
Natural killer (NK):dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity
Steve C. Lee et al.
IMMUNOLOGIC RESEARCH (2011)
Platinum-based chemotherapy plus cetuximab in head and neck cancer
Jan B. Vermorken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
JA Bonner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)